Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PYXS Pyxis Oncology Inc
- Stocks
- Healthcare
- NASDAQ: PYXS
Price (delayed)
$1.13
Market cap
$69.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$68.85M
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype
Highlights
PYXS's quick ratio has surged by 55% year-on-year
Pyxis Oncology's debt has decreased by 5% YoY
PYXS's EPS is up by 29% year-on-year but it is down by 28% since the previous quarter
Pyxis Oncology's net income has decreased by 35% QoQ and by 4.8% YoY
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
Key stats
What are the main financial stats of PYXS
Market
Valuations
Earnings
Shares outstanding
61.59M
Market cap
$69.6M
Enterprise value
$68.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
4.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.26
Revenue
$16.15M
Gross profit
$15.67M
Operating income
-$89.46M
Net income
-$77.33M
EBIT
-$79.5M
EBITDA
-$75.81M
Free cash flow
-$57.91M
Per share
Balance sheet
Liquidity
EPS
-$1.32
EPS diluted
-$1.32
Free cash flow per share
-$0.99
Book value per share
$2.03
Revenue per share
$0.28
TBVPS
$2.64
Total assets
$157.18M
Total liabilities
$36.43M
Debt
$20.2M
Equity
$120.75M
Working capital
$114.76M
Debt to equity
0.17
Current ratio
7.49
Quick ratio
7.26
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-469.5%
Gross margin
97.1%
Net margin
-478.9%
Operating margin
-554.1%
Return on assets
-39.6%
Return on equity
-49.2%
Return on invested capital
-50.4%
Return on capital employed
-57%
Return on sales
-492.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PYXS stock price
How has the Pyxis Oncology stock price performed over time
Intraday
3.67%
1 week
-10.32%
1 month
14.67%
1 year
-74.94%
YTD
-27.56%
QTD
15.32%
Financial performance
How have Pyxis Oncology's revenue and profit performed over time
Revenue
$16.15M
Gross profit
$15.67M
Operating income
-$89.46M
Net income
-$77.33M
Gross margin
97.1%
Net margin
-478.9%
Pyxis Oncology's net margin has decreased by 35% QoQ
Pyxis Oncology's net income has decreased by 35% QoQ and by 4.8% YoY
The operating income has decreased by 33% from the previous quarter and by 9% YoY
PYXS's operating margin is down by 33% since the previous quarter
Price vs fundamentals
How does PYXS's price correlate with its fundamentals
Growth
What is Pyxis Oncology's growth rate over time
Valuation
What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
0.56
P/S
4.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.26
PYXS's EPS is up by 29% year-on-year but it is down by 28% since the previous quarter
PYXS's P/B is 55% below its last 4 quarters average of 1.2
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
PYXS's P/S is 65% below its last 4 quarters average of 11.3
Efficiency
How efficient is Pyxis Oncology business performance
PYXS's return on sales is down by 39% since the previous quarter
Pyxis Oncology's ROA has decreased by 38% from the previous quarter but it has increased by 3.6% YoY
The ROIC has decreased by 38% from the previous quarter but it has increased by 2.3% YoY
The return on equity has declined by 36% since the previous quarter but it rose by 6% year-on-year
Dividends
What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PYXS.
Financial health
How did Pyxis Oncology financials performed over time
PYXS's current ratio has surged by 55% year-on-year and by 2.2% since the previous quarter
PYXS's quick ratio has surged by 55% year-on-year
Pyxis Oncology's debt is 83% lower than its equity
The debt to equity rose by 31% since the previous quarter
The equity has contracted by 21% from the previous quarter and by 3.9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.